lung cancer study group
Recently Published Documents


TOTAL DOCUMENTS

125
(FIVE YEARS 9)

H-INDEX

22
(FIVE YEARS 1)

2021 ◽  
Vol 11 ◽  
Author(s):  
Yukihiro Toi ◽  
Takao Kobayashi ◽  
Toshiyuki Harada ◽  
Taku Nakagawa ◽  
Yoshiaki Mori ◽  
...  

BackgroundDiarrhea post-antibiotic use is primarily attributed to mucosal lesions induced by Clostridium (Clostridioides) difficile (C. difficile) infection (CDI). Cancer patients undergoing chemotherapy might have a higher risk of CDI even when prior antibiotics are not used. Thus far, the relationship between lung cancer chemotherapy and the incidence of diarrhea remains unclear. This prospective multicenter study aimed to determine the incidence of CDI in lung cancer patients undergoing chemotherapy.MethodsThe presence of C. difficile and its toxins was investigated in lung cancer patients experiencing diarrhea during chemotherapy including paclitaxel (PTX), nanoparticle albumin-bound paclitaxel (nab-PTX), docetaxel (DOC), tegafur-gimeracil-oteracil (S-1), or irinotecan (CPT-11). If grade 2 or higher diarrhea occurred, then a stool culture was performed to detect anaerobic organisms and C. difficile toxins A and B. Additional data were collected through patient interviews and medical chart review.ResultsA total of 263 consecutive patients were enrolled in the study; grade 2 or higher diarrhea was observed in 22 patients (8.4%); CDI was confirmed in five of them (1.9%). The incidence of CDI was 22.7% of all diarrhea cases, and 50% of patients treated with PTX were CDI positive; the incidence of CDI was significantly higher in patients treated with PTX (P=0.039). Among the diarrhea cases, CDI patients had significantly worse ECOG performance status (PS) (P=0.043) and a significantly higher neutrophil count (P=0.028) than non-CDI patients. No CDI patients received antibiotics before cancer chemotherapy.ConclusionsAlthough diarrhea does not always affect a large portion of lung cancer chemotherapy recipients, clinicians should consider the possibility of CDI occurrence in lung cancer patients receiving chemotherapy, particularly PTX, without prior antibiotic exposure.



2021 ◽  
Vol 8 ◽  
Author(s):  
Chunguo Wang ◽  
Sikai Wu ◽  
Rongwei Zhang ◽  
Ke Jin ◽  
Yicheng Qian ◽  
...  

Background: In 1995, a clinical randomized controlled study (RCT) conducted by the Lung Cancer Study Group (LCSG) pointed out that the lobectomy was the gold standard for treating early lung cancer. However, with the development of technology, the results of several retrospective studies have shown that the efficacy of pulmonary segmentectomy is equivalent to that of lobectomy. Currently, it is still controversial whether segmental resection or lobectomy should be performed for early lung cancer. Thus, we aim to summarize the indications of segmentectomy.Methods: To conduct the review, previous researches involving indications of segmentectomy were collected from the literature using Pubmed. These articles were published and accepted in English in the medical literature from 2013 to 2020. We have focused on segmentectomy and its indications.Results: A total of 176 articles were retrieved from the Pubmed database, of which 31 articles included indications for segmentectomy. We summarized the relevant content, and the potential and prospect of segmentectomy for the treatment of lung cancer were emphasized.Conclusions: These findings have a number of important implications for future practice. Pulmonary segmentectomy is a very vital surgical procedure for select patients with lung cancer, which provides a novel approach for the treatment of lung cancer and the survival of lung cancer patients.



2021 ◽  
Vol 16 (3) ◽  
pp. S285-S286
Author(s):  
F. Estevinho ◽  
A. Figueiredo ◽  
F. Barata ◽  
A. Barroso ◽  
U. Brito ◽  
...  






2020 ◽  
Vol 50 (5) ◽  
pp. 502-511
Author(s):  
Hidehito Horinouchi ◽  
Yuichiro Ohe

Abstract The Japan Clinical Oncology Group Lung Cancer Study Group has been carrying out clinical studies, exploring new strategies of treatment, supportive therapies (antiemetics, etc.), etc., for a variety of cancers, including not only small cell lung cancer and non-small cell lung cancer but also rare chest tumours (represented by thymoma) and cancer-associated conditions (cancerous pericarditis, cancerous pleuritis, etc.). In this review, an overview of all studies conducted from 1985 to 2019 is provided.



Lung Cancer ◽  
2020 ◽  
Vol 139 ◽  
pp. 89-93 ◽  
Author(s):  
Yoko Tsukita ◽  
Akira Inoue ◽  
Shunichi Sugawara ◽  
Shoichi Kuyama ◽  
Taku Nakagawa ◽  
...  


2019 ◽  
Vol 59 (3) ◽  
pp. 324-328
Author(s):  
Go Makimoto ◽  
Katsuyuki Hotta ◽  
Isao Oze ◽  
Kiichiro Ninomiya ◽  
Masamoto Nakanishi ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document